<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>YAGUE_PRETUMOR_DRUG_RESISTANCE_DN</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            YAGUE_PRETUMOR_DRUG_RESISTANCE_DN
        </div>
        <div class="card-body">
                <p>Resistance to chemotherapy is one of the principal causes of cancer mortality and is generally considered a late event in tumor progression. Although cellular models of drug resistance have been useful in identifying the molecules responsible for conferring drug resistance, most of these cellular models are derived from cell lines isolated from patients at a late stage in cancer progression. To ask at which stage in the tumorigenic progression does the cell gain the ability to acquire drug resistance, we generated a series of pre-tumorigenic and tumorigenic cells from human embryonic skin fibroblasts by introducing, sequentially, the catalytic subunit of telomerase, SV40 large T and small T oncoproteins, and an oncogenic form of ras. We show that the ability to acquire multidrug resistance (MDR) can arise before the malignant transformation stage. The minimal set of changes necessary to obtain pre-tumorigenic drug-resistant cells is expression of telomerase and inactivation of p53 and pRb. Thus, the pathways inactivated during tumorigenesis also confer the ability to acquire drug resistance. Microarray and functional studies of drug-resistant pre-tumorigenic cells indicate that the drug efflux pump P-glycoprotein is responsible for the MDR phenotype in this pre-tumorigenic cell model.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M2070">M2070</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:55691">ncbigene:55691</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7145">ncbigene:7145</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8642">ncbigene:8642</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6239">ncbigene:6239</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1295">ncbigene:1295</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:29940">ncbigene:29940</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:55752">ncbigene:55752</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:176">ncbigene:176</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:4313">ncbigene:4313</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1462">ncbigene:1462</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9697">ncbigene:9697</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:800">ncbigene:800</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:4053">ncbigene:4053</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M2070&#39;, name=&#39;YAGUE_PRETUMOR_DRUG_RESISTANCE_DN&#39;), definition=&#39;Resistance to chemotherapy is one of the principal causes of cancer mortality and is generally considered a late event in tumor progression. Although cellular models of drug resistance have been useful in identifying the molecules responsible for conferring drug resistance, most of these cellular models are derived from cell lines isolated from patients at a late stage in cancer progression. To ask at which stage in the tumorigenic progression does the cell gain the ability to acquire drug resistance, we generated a series of pre-tumorigenic and tumorigenic cells from human embryonic skin fibroblasts by introducing, sequentially, the catalytic subunit of telomerase, SV40 large T and small T oncoproteins, and an oncogenic form of ras. We show that the ability to acquire multidrug resistance (MDR) can arise before the malignant transformation stage. The minimal set of changes necessary to obtain pre-tumorigenic drug-resistant cells is expression of telomerase and inactivation of p53 and pRb. Thus, the pathways inactivated during tumorigenesis also confer the ability to acquire drug resistance. Microarray and functional studies of drug-resistant pre-tumorigenic cells indicate that the drug efflux pump P-glycoprotein is responsible for the MDR phenotype in this pre-tumorigenic cell model.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;17283147&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;55691&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7145&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8642&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6239&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1295&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;29940&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;55752&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;176&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;4313&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1462&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9697&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;800&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;4053&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Jessica Robertson&#39;], &#39;exact_source&#39;: [&#39;Table 2: Down-regulated in resistant cells&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>